Background: Complement mediated autoimmunity against aquaporin-4 results in astrocytic damage in neuromyelitis optica (NMO). There is evidence for increased CSF glial fibrillary acidic protein (GFAP) and S100B levels in acute NMO. Here we tested whether the CSF finding also holds true for the diagnostic value of serum GFAP and S100B levels in NMO. Methods: A multicentre study included 322 patients from London (n = 160), Nijmegen (n= 95), Pecs (n= 44), and Lyon (n= 24). Patients were classified into the following diagnostic categories: neurological control patients (n= 45), MS optic neuritis (MSON, n = 38), isolated optic neuritis (ION, n = 11), relapsing isolated optic neuritis (RION, n = 48), chronic relapsing isolated optic neuropathy (CRION, n = 18), unclassified optic neuritis (UCON, n = 39), NMO (n= 77) and relapsing remitting multiple sclerosis (RRMS, n = 47). Serum GFAP and S100B levels were quantified using ELISA. Results: Median serum GFAP but not S100B levels were significantly higher (pb 0.0001, general linear model) in patients with NMO (4.83 pg/mL) if compared to MSON (1.5 pg/mL, p = 0.0001), UCON (1.92 pg/mL, p b 0.01), ION (0.0 ng/mL, p b 0.05), RION (1.3 pg/mL, p b 0.0001) and CRION (2.2 pg/mL, p = 0.01). Serum GFAP levels in the control cohort (3.6 pg/mL) were not significantly different to NMO. There was no relationship between serum GFAP levels and any other clinical or demographic parameter. Serum S100B concentrations correlated with the number of relapses in MSON (R = 0.83, p = 0.005). Conclusion: In contrast to the CSF, neither serum GFAP nor S100B levels were of major diagnostic value for the laboratory supported differential diagnosis between optic neuritis in the context of NMO and other optic neuropathies.
Introduction
The auto-antibody (NMO-IgG) described by Lennon et al. [1] binds to the plasma membrane protein AQP4 expressed at the astrocytic endfeet that abut capillaries and pia [2] . Autoimmunity against aquaporin-4 (AQP4) [1, 3, 4] damages the astrocytes, particularly in the AQP4 rich areas of the central nervous system (CNS) such as the optic nerve and spinal cord [5] . The precise mechanism by which the NMO-IgG acts is not known, but complement activation leading to astrocytic necrosis has been shown by a number of groups [6] [7] [8] . In addition, there is experimental evidence for glutamate mediated excitotoxicity [8] . Following astrocytic destruction, cellular proteins such as glial fibrillary acidic protein (GFAP) are released leading to significantly elevated CSF GFAP levels during an acute relapse in NMO [9] [10] [11] [12] . The specificity of GFAP as a biomarker for astrocytic damage is high. Another slightly less specific glial biomarker, S100B was also significantly elevated in the CSF during an acute relapse of NMO [11, 12] . Compared to GFAP, S100B is less specific for astrocytic damage because it is also expressed by microglia and oligodendrocytes of the CNS. Naturally the question arises whether the substantial increase of GFAP and S100B levels in the CSF would also be reflected in the patient's serum.
This prospective study investigated the value of serum GFAP and S100B levels for the differential diagnosis of NMO in comparison with optic neuritis associated with MS and three other syndromically defined varieties of inflammatory optic neuropathy in which there is evidence of neither MS nor NMO [13] .
Patients and methods
The study was approved by the local Institutional Review Board (IRB), informed consent was obtained and samples exchanged using material transfer agreements.
Patients
This prospective study included 371 patients recruited between January 2000 and July 2010 at four European centres: London (United Kingdom), Lyon (France), Nijmegen (The Netherlands) and Pecs (Hungary). The study included the cohort of 17 patients from London which has been the subject of a preliminary report [14] .
Inclusion criteria for NMO were as published by Wingerchuk et al. [15] . Of note, in these criteria seropositivity for anti AQP4 antibodies was not a pre-requisite and by no means the only test performed. Clearly, MRI was required [16] to allow for the distinction between classical NMO [15] and the NMO spectrum disorder [17] . Inclusion criteria for MS were the 2001 McDonald criteria [18] . Inclusion criteria for isolated optic neuritis (ION), multiple sclerosis optic neuritis (MSON), relapsing isolated optic neuritis (RION) and chronic relapsing inflammatory optic neuropathy (CRION) were as described [13, 19] . Briefly, a diagnosis of CRION was made in patients who always relapsed directly after withdrawing immunosuppressive treatment and in whom MRI showed pathology restricted to the optic nerve; a diagnosis of RION was made in patients who had a spontaneous relapse of their optic neuritis and in whom MRI showed pathology restricted to the optic nerve; a diagnosis of ION was made in patients who had one single episode of optic neuritis and in whom MRI showed pathology restricted to the optic nerve. Patients with optic neuritis not fitting any of the above categories were classified as UCON (unclassified optic neuritis). A typical patient with UCON would be one presenting with a single episode of optic neuritis in whom the MRI of the brain was not entirely normal, but not typical for MS or NMO. Of note, in the present study the AQP4 serostatus was not used for classification of patients with ION, RION or UCON as "NMO spectrum disorders" which represent an umbrella for NMO related systemic autoimmunity relationships now also embracing rheumatologic diseases such as systemic lupus erythematosus and Sjögren syndrome [20, 21] .
Exclusion criteria were any other severe neurological condition such as a brain tumour, a cerebrovascular accident, cerebral vasculitis, subarachnoid haemorrhage, traumatic brain injury, meningo-encephalitis or siderosis.
Serum samples
Blood samples were collected in vacuum tubes. Samples were spun at 2000 g for 10 min at room temperature. Aliquots were taken and stored in 1.5 mL polypropylene tubes at − 80°C until further analysis. Samples were shipped on dry ice to Amsterdam. All samples arrived safe, still with sufficient dry ice. All serum analyses were done at a single laboratory (Amsterdam) with the analysts (M.G. and A.P.) being blinded to all other demographic and clinical details.
GFAP ELISA
A previously described GFAP ELISA [22] was modified because of change of antibody and protein suppliers as follows: microtitre plates were coated overnight with 100 μL of the mouse monoclonal SMI26 capture antibody (SMI-26R, Covance) and diluted 1/5000 in 0.05 M carbonate buffer, pH 9.5. The plate was washed with barbitone buffer containing 6 mM EDTA, 0.2% BSA and 0.05% Tween 20 (pH 8.6). The plate was blocked with 150 μL of barbitone buffer containing 6 mM EDTA and 2% of BSA. After washing, 50 μL of barbitone buffer, 6 mM EDTA, and 0.2% BSA were added as sample diluent to each well. Fifty microlitres of standard or serum sample was then added in duplicate to the plate. Because of the large number of batch analysed samples, pipetting time exceeded the previously published 1 h incubation period [22] . The plate was incubated at 4°C overnight. After washing, 100 μL of rabbit polyclonal anti bovine GFAP (Z0334, DAKO) diluted 1:1000 in barbitone buffer (6 mM EDTA, 0.2% BSA) was added to each well and the plate was incubated for 1 h at RT. Following another one hour incubation period and wash cycle the reporter antibody (HRP swine anti-rabbit, P0217, DAKO) was added. After a final one hour incubation and wash cycle, 100 μL of TMB substrate was added. The plate was incubated for 20 min at RT in the dark, the reaction was stopped by adding 50 μL 2 M H 2 SO 4 and the absorbance was read at 450 nm with 540 nm as the reference wavelength on an ELISA plate reader.
The averaged measurement accuracy of the duplicates calculated to a coefficient of variation of 3.9.
S100B ELISA
A previously described serum S100B ELISA [23] was modified because of change of antibody and protein suppliers as follows: 96-well micrometre plates were coated with 100 μL 0.05 M carbonate buffer containing mouse monoclonal anti S100B (S2532, Sigma). The plates were washed with 0.67 M barbitone buffer containing 5 mM calcium lactate, 0.2% BSA and 0.05% Tween and then blocked with 150 μL of 2% BSA and washed again. Diluted serum (1:1) in 0.67 M barbitone buffer containing 5 mM calcium lactate was added in duplicate. After incubation (as for GFAP at 4°C, overnight) and wash polyclonal rabbit anti S100B (HPA015768, Sigma) was added. Following another one hour incubation period and wash cycle the reporter antibody (HRP swine anti-rabbit, P0217, DAKO) was added. After a final one hour incubation and wash cycle, the plate was incubated for 20 min at RT in the dark, the reaction was stopped by adding 50 μL 2 M H 2 SO 4 and the absorbance was read at 450 nm with 540 nm as the reference wavelength on an ELISA plate reader.
The averaged measurement accuracy of the duplicates calculated to a coefficient of variation of 4.8.
AQP4 serology
The serostatus for AQP4 was determined using different assays. For the French cohort we used a cell-based assay with HEK transfected with high amount of AQP4-M1 isoform as described [8] . For the Hungarian cohort we used two cell-based assays, a commercially available one (EUROIMMUN AG, Lübeck, Germany) and an in-house assay kindly provided by the group of Bernhard Hemmer [24] . For the Dutch cohort samples were analysed by a commercial kit (Sanquin, Amsterdam, The Netherlands) [25] . For the English cohort samples were analysed by the cell-based assay from Euroimmune and partly at the Mayo-Clinic (Rochester) as described [1] .
Statistics
Statistical analyses were performed using SAS software (V 9.1). Because of non-normal distribution the median and interquartile range (IQR) were presented. Independent variables were compared using the Kruskal-Wallis test and general linear models (GLM). General linear models (GLM) were also used to control for fixed effects. Categorical variables were compared using the Chi-square test. The linear relationship between continuous variables was evaluated using the non-parametric Spearman correlation coefficient. Cutoff values were calculated using receiver operator characteristics (ROC). The area under the curve (AUC), sensitivity and specificity levels were presented for serum GFAP and serum S100B. Multiple correlations were corrected using the Bonferroni method. Two-tailed tests were used throughout and p values of b0.05 were accepted as significant.
Results
In this multicentre setting there was a recruitment bias of patients per disease group reflecting on the local expertise (Table 1) . Most patients with neuro-ophthalmological conditions came from London. Most control patients and RRMS patients came from Nijmegen. For the study group, NMO 27/77 (35%) came from London, 27% from Lyon, 5% from Nijmegen and 32% from Pecs. Importantly, there was no geographic or pre-analytical bias introduced and serum GFAP levels between NMO patients from different towns were comparable (p = 0.15). Overall, there was a significant age difference between the groups with RION and MSON patients representing the youngest cohort (F 7,315 = 5.11, p b 0.0001, Table 1 ).
Phenotype relationship
The serum GFAP levels were significantly different between groups (F 7,315 = 5.11, p b 0.001, Fig. 1 ). The difference in serum GFAP levels did not depend on age (p = 0.99) and serum GFAP levels did not correlate with age (R = −0.006, p = 0.9).
The median serum GFAP levels were significantly higher in patients with NMO (4.83 pg/mL) if compared to MSON (1.5 pg/mL, p = 0.0001), UCON (1.92 pg/mL, p b 0.01), ION (0.0 pg/mL, p b 0.05), RION (1.3 pg/mL, p b 0.0001) and CRION (2.2 pg/mL, p = 0.01). The ROC analysis for serum GFAP levels as a diagnostic test for NMO revealed an AUC of 0.754 with an optimised cutoff level of 3.01 pg/mL GFAP. Based on this cutoff level the diagnostic sensitivity of serum GFAP for NMO was 23% with a specificity of 33%.
The serum S100B levels did not differ statistically between groups (p = 0.55). Therefore no further ROC analyses were performed. Serum S100B levels did not correlate with age (R = 0.055, p = 0.43).
Likewise, a post-hoc analyses on a pooled group of patients with ION and RION who were AQP4 seropositive with those who were not did not reveal any statistical significant difference for either serum GFAP or S100B levels (data not shown).
NMO subgroups
Patients with NMO were dichotomised according to their clinical presentation into those with an acute myelitis (n = 55) and those without (n = 22). There was no statistical significant difference between the two groups (p = 0.39).
Timing of sample acquisition
Because CSF GFAP and S100B levels were reported to be higher during a relapse compared to remission [9, 10, 12] we tested whether this is also the case for serum concentrations. The median serum GFAP levels during a relapse were 4.6 pg/mL (IQR 2.4-7.4 pg/mL) in NMO compared to 2.6 ng/mL (0-5.2 pg/mL, p = 0.33) in remission. Reliable data on the timing of the relapse was not available in 25 patients. The median serum S100B levels during a relapse were Table 1 Patient demographics. UK = United Kingdom, F = France, NL = The Netherlands, HR = Hungary, CTRL = controls, MSON = multiple sclerosis optic neuritis, ION = isolated optic neuritis, RION = relapsing isolated optic neuritis, CRION = chronic relapsing isolated optic neuropathies, UCON = atypical optic neuritis, NMO = neuromyelitis optica, RRMS = relapsing remitting multiple sclerosis. The median (range), the number (%) is shown, AQP4-ab = anti-AQP4 auto-antibodies, n.d. = not determined, the proportion of AQP4-ab positive samples of the total number of samples tested (%) is shown. 1.2 ng/mL (IQR 0.8-1.5 ng/mL) in NMO compared to 1.4 ng/mL (0.6-2.1 ng/mL, p = 0.70) in remission. For patients with RRMS serum GFAP levels during a relapse were 5.0 pg/mL (0-7.3 pg/mL) compared to 3.2 pg/mL (0.8-5.0 pg/mL, p = 0.57) in remission. The serum S100B levels were 1.7 ng/mL (0.7-2.8 ng/mL) compared to 2.0 ng/mL (1.0-2.0 ng/mL, p = 0.47) in remission.
There was no significant correlation of either serum GFAP or serum S100B levels with the delay between onset of relapse and time of sampling in any of the disease groups (data not shown).
Disease activity as assessed by the number of relapses correlated with serum S100B levels in MSON patients (Fig. 3) .
Biomarker relationships
In patients with RION tested positive for antibodies against AQP4 serum GFAP levels were significantly higher, 7.9 pg/mL (6.4-10.5 pg/mL) compared to AQP4 seronegative patients, 1.3 pg/mL (0-2.3 pg/mL, p = 0.0028, Fig. 2 ). There was no statistical difference for serum GFAP or S100B levels in NMO based on the AQP4 serostatus.
There was no significant correlation between the concentration of serum GFAP and serum S100B in any of the disease groups.
Discussion
The main finding of this study is higher median serum GFAP levels in patients with NMO (4.83 pg/mL) compared to patients with other forms of optic neuropathy (1.5-2.2 pg/mL). These data support the hypothesis that complement mediated autoimmunity against AQP4 leads to astrocytic damage and causes release of GFAP [6, 7, 11] . In contrast to the concentration of GFAP in the CSF the serum concentration is only of minor diagnostic value for NMO. The data on serum GFAP levels from specific cohorts of optic neuropathies [13] is further offset by the large overlap with the serum GFAP concentration in neurological controls in which no overt pathology was found (Fig. 1) . The minor diagnostic value of serum GFAP levels is further underlined by the low specificity limit of 33%. In this study serum S100B levels were not of diagnostic value for NMO.
In this cross-sectional study serum GFAP and S100B levels were not statistically influenced by the timing of serum sampling with either relation to relapse/remission or time delay from an acute relapse. There was, however a trend for almost two-fold higher median serum GFAP levels during a relapse (4.6 pg/mL) compared to remission (2.6 pg/mL) and the study may have been underpowered to reveal this difference on a statistical level. Notably, data on presence of a relapse was ambiguous in 25 patients. On the other hand and in view of previously published work [26] [27] [28] [29] , the data may suggest, at least on a group level, that the concentrations of GFAP and S100B in the serum are poorly correlated to the concentrations found in the CSF compartment. For S100B, there are a number of studies demonstrating that serum and CSF levels were not correlated in a number of diseases including MS [26] [27] [28] [29] . Likewise, a recent study on serum GFAP and S100B levels in NMO did not find a correlation of concentrations between body fluid compartments [30] . In contrast to these results one study did find in AQP4 autoantibody positive patients that serum and CSF levels of both glial biomarkers were highly correlated [31] . In this respect a shortcoming of our study is that we only had access to serum samples for analysis.
Another limitation of our study is a patient referral bias due to the multicentre setting with different clinical focuses. Almost all patients with optic neuropathies other than NMO were recruited in London. This may be relevant because of the classification in ION, RION and UCON based on clinical and MRI data. Inspection of Table 1 shows an 11% AQP4 seropositive rate for patients with UCON and RION. This is very similar to the 10% AQP4 seropositive rate found for the overlap with systemic rheumatoid diseases [20, 21] . Two large studies on AQP4 antibodies in patients with different forms of optic neuropathies found about 5-6% to be seropositive [13, 32] which is less than the 25% reported in the original paper describing the antibody [1] . We would be hesitant to draw any conclusions on the diagnostic value of serum GFAP levels in this context, but long-term follow up studies of these patients including a more extensive and standardised auto-antibody panel titres may be informative. Such studies are warranted because if a link to systemic rheumatoid autoimmunity can be demonstrated, rigorous immunosuppression may be required for protection of visual function.
A further limitation of our study was that we were not able to compare the sensitivity and specificity levels of serum GFAP and/or S100B levels to the AQP4 serostatus for two reasons. First, different assays for presence of AQP4 auto-antibodies were used in this multicentre study [1, 8, 24, 25] . There are likely significant differences of the analytical sensitivity between these assays as assessed by a blinded multicentre study. On the other side this situation is not uncommon in a multi-centre setting and has been discussed extensively [21] . Second, for this study samples were analysed in all NMO patients, but not systematically in all patients of the other groups. In this context it should be mentioned that at the start of this prospective study the AQP4 auto-antibody had not yet been discovered.
A major shortcoming of our study is that the aetiopathogenesis of MSON, ION, RION and CRION remains unknown. There is no biological evidence showing that the aetiology of MSON is different from the aetiology of RION. The same applies to the difference between CRION and neurosarcoidosis as already discussed [19] . Another shortcoming was that we did not have systematic longitudinal clinical data to assess the potential prognostic value of serum GFAP levels in this cohort. These major limitations aside, the present data supports the concept of more substantial glial pathology in NMO compared to MS or other optic neuropathies. Importantly, this was the case independent to whether or not patients with NMO presented with an acute myelitis. For NMO, at least, there is good experimental evidence for complement mediated autoimmune damage to the astrocytes. It is therefore plausible to assume that the observed increase of serum GFAP levels is related to the underlying pathology.
It is not surprising to note that serum S100B levels were not of diagnostic value because an elevation of the concentration of S100B is also reported in a range of other acute neurological diseases Fig. 3 . In patients with MSON, serum S100B levels correlated with disease activity as assessed by the number of relapses (R = 0.83, p = 0.005). [33, 34] . In addition, there are many extracranial sources of S100B [35] likely to introduce measurement noise. The data on higher serum S100B levels in patients with more active MS is consistent with previous studies suggesting serum S100B to be a biomarker for micro-and macroglial activity [29, 36] . Because the more disseminated pathology in the MS brain compared to local pathology in optic neuropathies, serum S100B levels may be investigated as a potential biomarker for controlling inflammatory disease activity in RR or SP MS, but not PPMS [37] .
Conclusion
This study demonstrates that unlike the considerable higher CSF GFAP and S100B levels in acute NMO compared to other neurological diseases [9] [10] [11] [12] , serum GFAP levels are of limited value in a highly selected cohort of patients with optic neuropathies and serum S100B levels are of no diagnostic value. 
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